<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401619</url>
  </required_header>
  <id_info>
    <org_study_id>BONEM2017294</org_study_id>
    <nct_id>NCT03401619</nct_id>
  </id_info>
  <brief_title>Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study</brief_title>
  <acronym>BONE</acronym>
  <official_title>Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study: an Ambispective, Multicentre, Open Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Education, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Municipal Science &amp; Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epigenetic modification refers to the change of heritable gene expression occurring in the
      case of unchanged DNA sequence, including DNA methylation, epigenetic modification, RNAS,
      chromatin modification, etc. The study found that osteoporosis (OSTEOPOROSIS,OP) with
      neurological disorders is very common, the risk of fracture of patients increased. It is
      considered that epigenetic regulation plays an important role in the occurrence and
      development of OP with neurological disorders. In particular, the role and molecular
      mechanism of epigenetic modification in OP with neurological disorders are not clear, and the
      results of clinical studies with different sample sizes are not consistent. (1) Two-way
      continuous queues,an ambispective cohort study， namely: forward-looking queue method
      (2017-2027) and Retrospective queue method (2007-2017) were used to understand the effect of
      epigenetic modification on bone mineral density, bone metabolic Biochemical Index, imaging
      index and fracture incidence of patients with neurological diseases in outpatients and wards,
      and to provide basis for further study. To observe the effects of epigenetic modification on
      cognitive function in two groups of patients (memory scale, life activity Energy meter (ADL)
      and cognitive scale (MMSE) and clinical physical examination and neuropsychological test,
      etc., Bone correlation detection (Lumbar and hip bone mineral density T-score, imaging index,
      bone Metabolic Biochemical Index and fracture incidence index) Influence. Multivariate
      stepwise regression analysis was performed to eliminate confounding factors, such as age,
      body mass index (BMI), related risk factors, and internal diseases. The patient's previous
      information is also analyzed; (2) To find meaningful epigenetic modification from clinical
      data, the molecular mechanism was studied in depth, and the imaging indexes (X-ray, CT, MRI)
      and Bone marker Index (serum osteocalcin (OC), total I-type procollagen peptide (TP1NP) were
      found in the study. Type I collagen hydroxy-terminated peptide beta degradation product
      (Β-CTX)). The relationship between the reaction epigenetic modification and cognitive
      function index, image and bone markers and the mechanism model were further established.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">September 22, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>cognitive impairment improvement</measure>
    <time_frame>year 1,2,3,4 and 5</time_frame>
    <description>Change from baseline in Mild Cognitive Impairment assessment scale-cognitive subscale in year 1,2,3,4 and 5</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Osteoporosis，Neurological Disorders</condition>
  <arm_group>
    <arm_group_label>Osteoporosis With Cognitive impairment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoporosis With Arterial stiffness</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoporosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.</intervention_name>
    <description>The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.</description>
    <arm_group_label>Osteoporosis With Cognitive impairment</arm_group_label>
    <arm_group_label>Osteoporosis With Arterial stiffness</arm_group_label>
    <arm_group_label>Osteoporosis</arm_group_label>
    <arm_group_label>Normal</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteer, outpatient, inpatient
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal hearing, vision, and pronunciation

          -  DEXA examination

        Exclusion Criteria:

          -  Mental retardation

          -  Blindness, deafness, and dumb

          -  Severe schizophrenia

          -  patients with multiple myeloma, bone metastases ，et al.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dongwei Fan, doctor</last_name>
    <phone>861013522421109</phone>
    <email>fdw@bjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongqiang Chen, doctor</last_name>
      <phone>861082265557</phone>
      <email>chenzq@bjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. Erratum in: Lancet Neurol. 2014 Aug;13(8):757.</citation>
    <PMID>24849862</PMID>
  </reference>
  <reference>
    <citation>Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014 Aug;13(8):788-94. doi: 10.1016/S1474-4422(14)70136-X. Erratum in: Lancet Neurol. 2014 Nov;13(11):1070.</citation>
    <PMID>25030513</PMID>
  </reference>
  <reference>
    <citation>Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013 Oct;12(10):957-65. doi: 10.1016/S1474-4422(13)70194-7. Epub 2013 Sep 4.</citation>
    <PMID>24012374</PMID>
  </reference>
  <reference>
    <citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011 Sep;10(9):819-28. doi: 10.1016/S1474-4422(11)70072-2. Epub 2011 Jul 19. Review.</citation>
    <PMID>21775213</PMID>
  </reference>
  <reference>
    <citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8.</citation>
    <PMID>23477989</PMID>
  </reference>
  <reference>
    <citation>Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1092-1099. doi: 10.1016/S1474-4422(14)70198-X. Epub 2014 Oct 5.</citation>
    <PMID>25297016</PMID>
  </reference>
  <reference>
    <citation>Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2.</citation>
    <PMID>26144908</PMID>
  </reference>
  <reference>
    <citation>Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2014 Dec;15(13):1460-8. doi: 10.1016/S1470-2045(14)71035-6. Epub 2014 Nov 11. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.</citation>
    <PMID>25456365</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Dongwei Fan</investigator_full_name>
    <investigator_title>Orthopeadic doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

